![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Early versus Delayed Hepatitis C Treatment Provides Increased Health Benefits at Lower Costs: A Pan-Genotypic Cost-Effectiveness Analysis Set in Scotland
|
|
|
risk of HCC reduced from 35% to 1.8% if treated in F0-1 vs F4, risk of liver related death decreased from 9.1% to 3.8% if treated in F0-1
Reported by Jules Levin
EASL - European Association for the
Study of the Liver (EASL) Paris, France 11 - 15 April 2018
Brett Pinsky1, Dominic Mitchell2, Yuri Sanchez Gonzalez1, Scott Johnson2; Sammy Saab3
1AbbVie, Inc., North Chicago, IL, USA; 2Medicus Economics, Boston, MA, USA; 3UCLA Medical Center, Los Angeles, CA, USA
![0423181](../images%20/042318/042318-7/0423181.gif)
![0423182](../images%20/042318/042318-7/0423182.gif)
![0423183](../images%20/042318/042318-7/0423183.gif)
![0423184](../images%20/042318/042318-7/0423184.gif)
![0423185](../images%20/042318/042318-7/0423185.gif)
![0423186](../images%20/042318/042318-7/0423186.gif)
![0423187](../images%20/042318/042318-7/0423187.gif)
![0423188](../images%20/042318/042318-7/0423188.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|